▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #806 by analyst upside · 2026-11-13
BCYC
Bicycle Therapeutics plc
Healthcare · Market Cap $242M · P/E 0x
ANALYST PRICE TARGET
+165.7%
implied upside to consensus target
Current Price $3.45
Consensus Target $9.17
Bull Target $14.0
Bear Target $5.0
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
3
Hold
2
Sell
0
52-Week Low $3.33
52-Week High $7.83
YTD Return -48.4%
FUNDAMENTALS
Market Cap $242M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.03
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $84M
Profit Margin -169.8%
52-WEEK RANGE
52-Week Low $3.33
52-Week High $7.83
Current Price $3.45
Bear Target $5.0
Bull Target $14.0
● Now $3.45 ● Target $9.17
TRADING DATA
Avg Volume 416K
YTD Return -48.4%
Analyst Count 6
Consensus Buy
Upside to Target +165.7%
Last Updated 2026-11-13

ANALYST SUMMARY

Bicycle Therapeutics plc (BCYC) is currently trading at $3.45 with a Wall Street consensus price target of $9.17, implying potential upside of 165.7% over the next 12 months. 6 analysts currently cover BCYC, with a consensus rating of Buy - 67% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $14.0, while the most cautious has a target of $5.0.

BCYC operates in the Healthcare sector with a market capitalisation of $242M. The stock is down 48.4% year-to-date and is currently trading near the lower end of its 52-week range of $3.33 – $7.83.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

CGEN +126.4%
Compugen Ltd.
$201M · P/E 5.4x · Buy
ELMD +94.2%
Electromed, Inc.
$204M · P/E 18.1x · Buy
PLX +271.6%
Protalix BioTherapeutics, Inc.
$250M · P/E 12.3x · Buy
CRMD +222.3%
CorMedix Inc.
$385M · P/E 2.4x · Strong Buy
XFOR +265.9%
X4 Pharmaceuticals, Inc.
$324M · P/E 5.8x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for BCYC, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Needham - Reiterated
Buy → Buy 2026-07-30 20% win rate (5 calls)
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-04-08 Building track record
Oppenheimer - Reiterated
Outperform → Outperform 2026-03-18 14% win rate (7 calls)
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-03-18 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-03-18 Building track record
Needham - Reiterated
Buy → Buy 2026-03-18 20% win rate (5 calls)
Truist Securities ● Initiated
Hold 2025-11-24 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2025-10-31 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
29
out of 100
Coverage depth
15/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →